Literature DB >> 32865636

Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: A systematic review and meta-analysis.

Se Jin Cho1, Jae Hyoung Kim2, Sung Hyun Baik1, Leonard Sunwoo1, Yun Jung Bae1, Byung Se Choi1.   

Abstract

PURPOSE: Preoperative MRI detection of post-laminar optic nerve invasion (PLONI) offers guidance in assessing the probability of total tumor resection, an estimation of the extent of surgery, and screening of candidates for eye-preserving therapies or neoadjuvant chemotherapies in the patients with retinoblastoma (RB). The purpose of this systematic review and meta-analysis was to evaluate the diagnostic performance of MRI for detecting PLONI in patients with RB and to demonstrate the factors that may influence the diagnostic performance.
METHODS: Ovid-MEDLINE and EMBASE databases were searched up to January 11, 2020, for studies identifying the diagnostic performance of MRI for detecting PLONI in patients with RB. The pooled sensitivity and specificity of all studies were calculated followed by meta-regression analysis.
RESULTS: Twelve (1240 patients, 1255 enucleated globes) studies were included. The pooled sensitivity was 61%, and the pooled specificity was 88%. Higgins I2 statistic demonstrated moderate heterogeneity in the sensitivity (I2 = 72.23%) and specificity (I2 = 78.11%). Spearman correlation coefficient indicated the presence of a threshold effect. In the meta-regression, higher magnetic field strength (3 T than 1.5 T), performing fat suppression, and thinner slice thickness (< 3 mm) were factors causing heterogeneity and enhancing diagnostic power across the included studies.
CONCLUSIONS: MR imaging was demonstrated to have acceptable diagnostic performance in detecting PLONI in patients with RB. The variation in the magnetic field strength and protocols was the main factor behind the heterogeneity across the included studies. Therefore, there is room for developing and optimizing the MR protocols for patients with RB.

Entities:  

Keywords:  Magnetic resonance imaging; Meta-analysis; Optic nerve; Retinoblastoma

Year:  2020        PMID: 32865636     DOI: 10.1007/s00234-020-02538-1

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  49 in total

1.  Risk factors for metastases in patients with retinoblastoma.

Authors:  E P Messmer; T Heinrich; W Höpping; E de Sutter; W Havers; W Sauerwein
Journal:  Ophthalmology       Date:  1991-02       Impact factor: 12.079

2.  Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution.

Authors:  F Khelfaoui; P Validire; A Auperin; E Quintana; J Michon; H Pacquement; L Desjardins; B Asselain; P Schlienger; P Vielh
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

3.  Optic nerve involvement in retinoblastoma.

Authors:  I Magramm; D H Abramson; R M Ellsworth
Journal:  Ophthalmology       Date:  1989-02       Impact factor: 12.079

4.  Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K Baez; J R Cater; P De Potter
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

5.  Relevance of CT and MRI in retinoblastoma for the diagnosis of postlaminar invasion with normal-size optic nerve: a retrospective study of 150 patients with histological comparison.

Authors:  Hervé J Brisse; Myriam Guesmi; Isabelle Aerts; Xavier Sastre-Garau; Alexia Savignoni; Livia Lumbroso-Le Rouic; Laurence Desjardins; François Doz; Bernard Asselain; Danièle Bours; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2007-05-04

6.  Outcome of patients with retinoblastoma and postlaminar optic nerve invasion.

Authors:  Guillermo L Chantada; Fernando Casco; Adriana C Fandiño; Susana Galli; Julio Manzitti; Marcelo Scopinaro; Enrique Schvartzman; María T G de Dávila
Journal:  Ophthalmology       Date:  2007-04-24       Impact factor: 12.079

7.  Anatomic relationship between lamina cribrosa, intraocular space, and cerebrospinal fluid space.

Authors:  Jost B Jonas; Eduard Berenshtein; Leonard Holbach
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-12       Impact factor: 4.799

8.  Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation.

Authors:  J E Kopelman; I W McLean; S H Rosenberg
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

9.  Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma.

Authors:  Xavier Sastre; Guillermo L Chantada; François Doz; Matthew W Wilson; Maria T G de Davila; Carlos Rodríguez-Galindo; Murali Chintagumpala; Patricia Chévez-Barrios
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

10.  Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation.

Authors:  Isabelle Aerts; Xavier Sastre-Garau; Alexia Savignoni; Livia Lumbroso-Le Rouic; Estelle Thebaud-Leculée; Didier Frappaz; Carole Coze; Caroline Thomas; Marion Gauthier-Villars; Christine Lévy-Gabriel; Hervé J Brisse; Laurence Desjardins; François Doz
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

View more
  2 in total

1.  MRI-based radiomics model can improve the predictive performance of postlaminar optic nerve invasion in retinoblastoma.

Authors:  Zhenzhen Li; Jian Guo; Xiaolin Xu; Wenbin Wei; Junfang Xian
Journal:  Br J Radiol       Date:  2021-12-03       Impact factor: 3.039

2.  Correlation between clinical presentations, radiological findings and high risk histopathological features of primary enucleated eyes with advanced retinoblastoma at Queen Sirikit National Institute of Child Health: 5 years result.

Authors:  Supawan Surukrattanaskul; Bungornrat Keyurapan; Nutsuchar Wangtiraumnuay
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.